Catalyst Repository | Adial Pharmaceuticals Inc Common Stock

Adial Pharmaceuticals Inc Common Stock

(NASDAQ:ADIL)

Description

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in phase 3 clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Charlottesville, Virginia.

ADIL Overview

None
Sector
Health Care
Industry
Major Pharmaceuticals

Previous Close
$0.2683
Previous Close Volume
274960